BioStem Technologies Acquires BioTissue's Surgical and Wound Care Business
January 22, 2026
BioStem Technologies (OTC: BSEM) has acquired the surgical and wound care business of BioTissue Holdings, Inc. for approximately $15 million upfront, with up to $25 million of contingent milestone and royalty payments. The deal includes the Neox and Clarix product lines, a nationwide commercial sales organization and assigned GPO contracts, expanding BioStem's access into hospital inpatient and outpatient wound-care markets and adding assets that generated roughly $29 million in 2025.
- Buyers
- BioStem Technologies, Inc.
- Targets
- BioTissue surgical and wound care business (BioTissue Holdings, Inc.)
- Sellers
- BioTissue Holdings, Inc.
- Industry
- Medical Devices
- Location
- Florida, United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
Axogen Acquires BioCircuit Technologies
September 10, 2026
Medical Devices
Axogen agreed to acquire BioCircuit Technologies for $200 million in cash, adding NerveTape, a sutureless peripheral nerve repair device, and related nerve-repair technologies to its portfolio. Axogen completed the acquisition on October 1, 2026; the deal expands its product capabilities and gives BioCircuit access to Axogen’s commercial, reimbursement, and hospital-contracting infrastructure.
-
Solventum Completes Acquisition of Acera Surgical
December 23, 2025
Healthcare Services
Solventum completed its acquisition of Acera Surgical, a privately held bioscience company focused on regenerative wound care. The deal includes $725 million in upfront cash plus up to $125 million in contingent cash payments tied to future milestones.
-
Merit Medical Systems Acquires Biolife Delaware
May 28, 2025
Medical Devices
Merit Medical Systems has acquired Biolife Delaware, a Sarasota, Florida-based maker of StatSeal and WoundSeal hemostatic devices, in a cash transaction valued at approximately $120 million (including assumed liabilities). The deal expands Merit's hemostasis and wound-care product portfolio and is expected to modestly impact 2025 non-GAAP profitability while enhancing Merit's ability to serve a broad set of percutaneous procedure end markets.
-
EmergentMedTech Merges with TRU Biologix
January 22, 2025
Biotechnology
EmergentMedTech announced a merger with TRU Biologix to integrate TRU Biologix's Wharton's Jelly–derived cell and tissue biologics into EmergentMedTech's regenerative medicine and aesthetics product portfolio. The deal expands EmergentMedTech's capabilities alongside its role as the exclusive U.S. distributor of NeoGen PSR, enabling delivery of advanced biologics to hundreds of clinics and clinician partners.
-
Bioventus Inc. Acquires Misonix, Inc.
July 29, 2021
Medical Devices
Bioventus Inc. entered into a definitive agreement to acquire Misonix, Inc. in a cash-and-stock transaction that values Misonix at approximately $518 million on a fully diluted basis. The deal expands Bioventus' regenerative medicine and surgical solutions portfolio by adding Misonix's minimally invasive ultrasonic technologies and regenerative wound products and is expected to close in the fourth quarter of 2021 subject to customary approvals.
-
StemBioSys Acquires Majority Stake in Cartox
January 8, 2020
Biotechnology
San Antonio-based StemBioSys acquired a majority stake in Ann Arbor startup Cartox, obtaining control with plans to purchase the remaining equity subject to milestones. The deal brings Cartox's cardiotoxicity imaging and assay capabilities together with StemBioSys's CELLvo extracellular matrix technology to accelerate commercial development of pre-clinical cardiac safety and efficacy screening solutions.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.